Search

Your search keyword '"Rusthoven, Chad G."' showing total 147 results
Start Over Author "Rusthoven, Chad G." Search Limiters Peer Reviewed
147 results on '"Rusthoven, Chad G."'

1. Stereotactic radiosurgery for brain metastases from human epidermal receptor 2 positive breast Cancer: an international, multi-center study

Author

Pikis, Stylianos, Mantziaris, Georgios, Protopapa, Maria, Tos, Salem M., Kowalchuk, Roman O., Ross, Richard Blake, Rusthoven, Chad G., Tripathi, Manjul, Langlois, Anne-Marie, Mathieu, David, Lee, Cheng-Chia, Yang, Huai-che, Peker, Selcuk, Samanci, Yavuz, Zhang, Michael Yu, Braunstein, Steve E., Wei, Zhishuo, Niranjan, Ajay, Lunsford, Dade L., and Sheehan, Jason

Published
2024
Full Text
View/download PDF

3. Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients

Author

Lehrer, Eric J., Khosla, Atulya A., Ozair, Ahmad, Gurewitz, Jason, Bernstein, Kenneth, Kondziolka, Douglas, Niranjan, Ajay, Wei, Zhishuo, Lunsford, L. Dade, Mathieu, David, Trudel, Claire, Deibert, Christopher P., Malouff, Timothy D., Ruiz-Garcia, Henry, Peterson, Jennifer L., Patel, Samir, Bonney, Phillip, Hwang, Lindsay, Yu, Cheng, Zada, Gabriel, Picozzi, Piero, Franzini, Andrea, Attuati, Luca, Prasad, Rahul N., Raval, Raju R., Palmer, Joshua D., Lee, Cheng-chia, Yang, Huai-che, Fakhoury, Kareem R., Rusthoven, Chad G., Dickstein, Daniel R., Sheehan, Jason P., Trifiletti, Daniel M., and Ahluwalia, Manmeet S.

Published
2023
Full Text
View/download PDF

4. Salvage Stereotactic Radiosurgery for Recurrent WHO Grade 2 and 3 Meningiomas: A Multicenter Study (STORM)

Author

Gallitto, Matthew, Sedor, Geoffrey, Lee, Albert, Pasetsky, Jared, Kinslow, Connor J., Santos, Genesis De Los, Obiri-Yeboah, Derrick, Kshettry, Varun R., Helis, Corbin A., Chan, Michael D., Beckham, Thomas H., McGovern, Susan L., Matsui, Jennifer, Palmer, Joshua D., Bell, Jonathan B., Mellon, Eric A., Lakomy, David, Huang, Jiayi, Boor, Ian, Rusthoven, Chad G., Sisti, Michael B., and Wang, Tony J.C.

Published
2024
Full Text
View/download PDF

7. Concurrent Administration of Immune Checkpoint Inhibitors and Single Fraction Stereotactic Radiosurgery in Patients With Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Brain Metastases is Not Associated With an Increased Risk of Radiation Necrosis Over Nonconcurrent Treatment: An International Multicenter Study of 657 Patients

Author

Lehrer, Eric J., Kowalchuk, Roman O., Gurewitz, Jason, Bernstein, Kenneth, Kondziolka, Douglas, Niranjan, Ajay, Wei, Zhishuo, Lunsford, L. Dade, Fakhoury, Kareem R., Rusthoven, Chad G., Mathieu, David, Trudel, Claire, Malouff, Timothy D., Ruiz-Garcia, Henry, Bonney, Phillip, Hwang, Lindsay, Yu, Cheng, Zada, Gabriel, Patel, Samir, Deibert, Christopher P., Picozzi, Piero, Franzini, Andrea, Attuati, Luca, Prasad, Rahul N., Raval, Raju R., Palmer, Joshua D., Lee, Cheng-chia, Yang, Huai-che, Harmsen, William S., Jones, Brianna M., Sharma, Sonam, Ahluwalia, Manmeet S., Sheehan, Jason P., and Trifiletti, Daniel M.

Published
2023
Full Text
View/download PDF

8. Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline

Author

Gondi, Vinai, Bauman, Glenn, Bradfield, Lisa, Burri, Stuart H., Cabrera, Alvin R., Cunningham, Danielle A., Eaton, Bree R., Hattangadi‐Gluth, Jona A., Kim, Michelle M., Kotecha, Rupesh, Kraemer, Lianne, Li, Jing, Nagpal, Seema, Rusthoven, Chad G., Suh, John H., Tomé, Wolfgang A., Wang, Tony J.C., Zimmer, Alexandra S., Ziu, Mateo, and Brown, Paul D.

Published
2022
Full Text
View/download PDF

11. Results of a Multi-Institutional Phase 2 Clinical Trial for 4DCT-Ventilation Functional Avoidance Thoracic Radiation Therapy

Author

Vinogradskiy, Yevgeniy, Castillo, Richard, Castillo, Edward, Schubert, Leah, Jones, Bernard L., Faught, Austin, Gaspar, Laurie E., Kwak, Jennifer, Bowles, Daniel W., Waxweiler, Timothy, Dougherty, Jingjing M., Gao, Dexiang, Stevens, Craig, Miften, Moyed, Kavanagh, Brian, Grills, Inga, Rusthoven, Chad G., and Guerrero, Thomas

Published
2022
Full Text
View/download PDF

14. Stereotactic radiosurgery for clinoid meningiomas: a multi-institutional study

Author

Bunevicius, Adomas, Pikis, Stylianos, Anand, Rithika Kormath, Nabeel, Ahmed M., Reda, Wael A., Tawadros, Sameh R., Abdelkarim, Khaled, El-Shehaby, Amr M. N., Emad, Reem M., Chytka, Tomas, Liscak, Roman, Caceres, Marco Perez, Mathieu, David, Lee, Cheng-chia, Yang, Huai-che, Picozzi, Piero, Franzini, Andrea, Attuati, Luca, Speckter, Herwin, Olivo, Jeremy, Patel, Samir, Cifarelli, Christopher P., Cifarelli, Daniel T., Hack, Joshua D., Strickland, Ben A., Zada, Gabriel, Chang, Eric L., Fakhoury, Kareem R., Rusthoven, Chad G., Warnick, Ronald E., and Sheehan, Jason

Published
2021
Full Text
View/download PDF

17. Sex Differences in Odds of Brain Metastasis and Outcomes by Brain Metastasis Status after Advanced Melanoma Diagnosis.

Author

Cioffi, Gino, Ascha, Mustafa S., Waite, Kristin A., Dmukauskas, Mantas, Wang, Xiaoliang, Royce, Trevor J., Calip, Gregory S., Waxweiler, Timothy, Rusthoven, Chad G., Kavanagh, Brian D., and Barnholtz-Sloan, Jill S.

Subjects
MELANOMA prognosis, BRAIN tumor diagnosis, MELANOMA diagnosis, SURVIVAL rate, RESEARCH funding, SEX distribution, LOGISTIC regression analysis, DESCRIPTIVE statistics, MULTIVARIATE analysis, METASTASIS, ODDS ratio, MEDICAL records, ACQUISITION of data, PROGRESSION-free survival, CONFIDENCE intervals, BRAIN tumors, OVERALL survival, PROPORTIONAL hazards models, DISEASE complications
Abstract

Simple Summary: Sex differences in cancer are well-established. However, less is known about sex differences in the diagnosis of brain metastasis and outcomes among patients with advanced melanoma. Using the nationwide Flatiron Health electronic health record-derived de-identified database, this study showed that males had greater odds of brain metastasis, and poorer real-world overall survival compared to females among those with brain metastasis, while there were no sex differences in clinical outcomes for those with advanced melanoma without brain metastasis. Sex differences in cancer are well-established. However, less is known about sex differences in diagnosis of brain metastasis and outcomes among patients with advanced melanoma. Using a United States nationwide electronic health record-derived de-identified database, we evaluated patients diagnosed with advanced melanoma from 1 January 2011–30 July 2022 who received an oncologist-defined rule-based first line of therapy (n = 7969, 33% female according to EHR, 35% w/documentation of brain metastases). The odds of documented brain metastasis diagnosis were calculated using multivariable logistic regression adjusted for age, practice type, diagnosis period (pre/post-2017), ECOG performance status, anatomic site of melanoma, group stage, documentation of non-brain metastases prior to first-line of treatment, and BRAF positive status. Real-world overall survival (rwOS) and progression-free survival (rwPFS) starting from first-line initiation were assessed by sex, accounting for brain metastasis diagnosis as a time-varying covariate using the Cox proportional hazards model, with the same adjustments as the logistic model, excluding group stage, while also adjusting for race, socioeconomic status, and insurance status. Adjusted analysis revealed males with advanced melanoma were 22% more likely to receive a brain metastasis diagnosis compared to females (adjusted odds ratio [aOR]: 1.22, 95% confidence interval [CI]: 1.09, 1.36). Males with brain metastases had worse rwOS (aHR: 1.15, 95% CI: 1.04, 1.28) but not worse rwPFS (adjusted hazard ratio [aHR]: 1.04, 95% CI: 0.95, 1.14) following first-line treatment initiation. Among patients with advanced melanoma who were not diagnosed with brain metastases, survival was not different by sex (rwOS aHR: 1.06 [95% CI: 0.97, 1.16], rwPFS aHR: 1.02 [95% CI: 0.94, 1.1]). This study showed that males had greater odds of brain metastasis and, among those with brain metastasis, poorer rwOS compared to females, while there were no sex differences in clinical outcomes for those with advanced melanoma without brain metastasis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE).

Author

Rusthoven, Chad G, Staley, Alyse W, Gao, Dexiang, Yomo, Shoji, Bernhardt, Denise, Wandrey, Narine, Shafie, Rami El, Kraemer, Anna, Padilla, Oscar, Chiang, Veronica, Faramand, Andrew M, Palmer, Joshua D, Zacharia, Brad E, Wegner, Rodney E, Hattangadi-Gluth, Jona A, Levy, Antonin, Bernstein, Kenneth, Mathieu, David, Cagney, Daniel N, and Chan, Michael D

Subjects
*NON-small-cell lung carcinoma, *BRAIN cancer, *BRAIN metastasis, *ANAPLASTIC lymphoma kinase, *EPIDERMAL growth factor receptors
Abstract

Introduction Historical reservations regarding stereotactic radiosurgery (SRS) for small-cell lung cancer (SCLC) brain metastases include concerns for short-interval and diffuse central nervous system (CNS) progression, poor prognoses, and increased neurological mortality specific to SCLC histology. We compared SRS outcomes for SCLC and non-small cell lung cancer (NSCLC) where SRS is well established. Methods Multicenter first-line SRS outcomes for SCLC and NSCLC from 2000 to 2022 were retrospectively collected (n = 892 SCLC, n = 4785 NSCLC). Data from the prospective Japanese Leksell Gamma Knife Society (JLGK0901) clinical trial of first-line SRS were analyzed as a comparison cohort (n = 98 SCLC, n = 814 NSCLC). Overall survival (OS) and CNS progression were analyzed using Cox proportional hazard and Fine-Gray models, respectively, with multivariable adjustment for cofactors including age, sex, performance status, year, extracranial disease status, and brain metastasis number and volume. Mutation-stratified analyses were performed in propensity score–matched retrospective cohorts of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) positive NSCLC, mutation-negative NSCLC, and SCLC. Results OS was superior for patients with NSCLC compared to SCLC in the retrospective dataset (median OS = 10.5 vs 8.6 months; P  < .001) and in the JLGK0901 dataset. Hazard estimates for first CNS progression favoring NSCLC were similar in both datasets but reached statistical significance in the retrospective dataset only (multivariable hazard ratio = 0.82, 95% confidence interval = 0.73 to 0.92, P  = .001). In the propensity score–matched cohorts, there were continued OS advantages for NSCLC patients (median OS = 23.7 [EGFR and ALK positive NSCLC] vs 13.6 [mutation-negative NSCLC] vs 10.4 months [SCLC], pairwise P values < 0.001), but no statistically significant differences in CNS progression were observed in the matched cohorts. Neurological mortality and number of lesions at CNS progression were similar for NSCLC and SCLC patients. Leptomeningeal progression was increased in patients with NSCLC compared to SCLC in the retrospective dataset only (multivariable hazard ratio = 1.61, 95% confidence interval = 1.14 to 2.26, P  = .007). Conclusions After SRS, SCLC histology was associated with shorter OS compared to NSCLC. CNS progression occurred earlier in SCLC patients overall but was similar in patients matched on baseline factors. SCLC was not associated with increased neurological mortality, number of lesions at CNS progression, or leptomeningeal progression compared to NSCLC. These findings may better inform clinical expectations and individualized decision making regarding SRS for SCLC patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved outcomes in patients with brain metastases: an international multicenter study of 697...

Author

Lehrer, Eric J., Ahluwalia, Manmeet S., Gurewitz, Jason, Bernstein, Kenneth, Kondziolka, Douglas, Niranjan, Ajay, Zhishuo Wei, Lunsford, L. Dade, Fakhoury, Kareem R., Rusthoven, Chad G., Mathieu, David, Trudel, Claire, Malouff, Timothy D., Ruiz-Garcia, Henry, Bonney, Phillip, Hwang, Lindsay, Cheng Yu, Zada, Gabriel, Patel, Samir, and Deibert, Christopher P.

Published
2023
Full Text
View/download PDF

47. The Role of Stereotactic Body Radiation Therapy in the Management of Liver Metastases.

Author

Lee, Sangjune Laurence, Bassetti, Michael F., and Rusthoven, Chad G.

Abstract

The liver is a common site for metastatic spread for various primary tumor histologies. Stereotactic body radiation therapy (SBRT) is a non-invasive treatment technique with broad patient candidacy for the ablation of tumors in the liver and other organs. SBRT involves focused, high-dose radiation therapy delivered in one to several treatments, resulting in high rates of local control. Use of SBRT for ablation of oligometastatic disease has increased in recent years and emerging prospective data have demonstrated improvements in progression free and overall survival in some settings. When delivering SBRT to liver metastases, clinicians must balance the priorities of delivering ablative tumor dosing while respecting dose constraints to surrounding organs at risk (OARs). Motion management techniques are crucial for meeting dose constraints, ensuring low rates of toxicity, maintaining quality of life, and can allow for dose escalation. Advanced radiotherapy delivery approaches including proton therapy, robotic radiotherapy, and real-time MR-guided radiotherapy may further improve the accuracy of liver SBRT. In this article, we review the rationale for oligometastases ablation, the clinical outcomes with liver SBRT, tumor dose and OAR considerations, and evolving strategies to improve liver SBRT delivery. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Concurrent Administration of Immune Checkpoint Inhibitors and Stereotactic Radiosurgery Is Well-Tolerated in Patients With Melanoma Brain Metastases: An International Multicenter Study of 203 Patients.

Author

Lehrer, Eric J., Gurewitz, Jason, Bernstein, Kenneth, Kondziolka, Douglas, Fakhoury, Kareem R., Rusthoven, Chad G., Niranjan, Ajay, Wei, Zhishuo, Lunsford, L. Dade, Malouff, Timothy D., Ruiz-Garcia, Henry, Peterson, Jennifer L., Bonney, Phillip, Hwang, Lindsay, Yu, Cheng, Zada, Gabriel, Deibert, Christopher P., Prasad, Rahul N., Raval, Raju R., and Palmer, Joshua D.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results